Stocks with the “Perfect 10” Smart Score on TipRanks have the potential to beat the market. It’s worth noting that stocks with this top score have historically surpassed the S&P 500 Index (SPX) by a huge margin. Today, using the Stock Screener tool, we’ve selected two stocks with a “Perfect 10” score and a Strong Buy consensus rating: XPO Logistics (NYSE:XPO) and Sarepta Therapeutics (NASDAQ:SRPT).
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
But before moving ahead, let’s take a look at how TipRanks calculates a Smart Score for stocks. Based on eight key market factors, including analyst ratings, and technical analysis, among others, the potential of a stock is evaluated. After considering these factors, a Smart Score between 1 and 10 is assigned to the stock, with 10 being the highest score.
Now, let’s let’s delve deeper into these two companies.
XPO Logistics, Inc.
XPO provides supply chain solutions, offering transportation and logistics services. Interestingly, the stock has received a “Perfect 10” Smart Score, as it met the requirements for six out of the eight parameters.
The company is benefiting from its efforts to reduce costs and improve customer service. Moreover, the company is well-positioned for long-term growth due to its ongoing network capacity expansion.
On TipRanks, the stock has a Strong Buy consensus rating based on 13 unanimous Buy ratings. The analysts’ average price target on XPO stock of $135.38 implies 31.3% upside potential from current levels. Over the past six months, shares of the company have gained 14.5%.
Sarepta Therapeutics, Inc.
Sarepta is a biopharmaceutical company that develops rare disease treatments. SRPT stock has cleared six out of the eight parameters to achieve a “Perfect 10” Smart Score.
The company’s top line is expected to benefit from the expansion of ELEVIDYS’ use in all Duchenne muscular dystrophy (DMD) patients aged 4 and older. In addition, SRPT’s efforts to develop another gene therapy targeting limb girdle muscular dystrophies (LGMD) might further boost Sarepta’s revenues.
Overall, Wall Street is optimistic about the stock. Sarepta has a Strong Buy consensus rating based on 14 Buys and four Holds. The analysts’ average price target on SRPT stock of $197.28 implies a 24.9% upside potential from current levels. Shares of the company have gained 61.5% in the past six months.
Concluding Thoughts
Investors seeking stocks with the potential to outperform the market could consider SRPT and XPO stocks. Their “Perfect 10” Smart Scores on TipRanks and efforts to improve performance increase the chances of beating the market. It is worth noting that investors can use TipRanks’ Experts Center tool to discover top stock picks as well.
